MS Sequencing: Part 6: Safety considerations when sequencing

 

Comment by Dr. Marc Girard
NeuroSens survey on sequencing – Part 6

When switching from one disease-modifying therapy (DMT) to another in patients with RRMS, consideration must be paid to the potential short- and long-term consequences of administering drugs in sequence.

It takes 30 seconds

* When selecting a new treatment in a patient with an inadequate response to a prior therapy, what is your main clinical consideration?

* Of the front-line therapies, which do you think is the least problematic to switch from?

* When switching from a front-line injectable DMT, what do you perceive to be the safest treatment to use next?

* When switching from a front-line oral DMT (teriflunomide or dimethyl fumarate), what do you perceive to be the safest treatment to use next?

* When escalating from a front-line therapy to fingolimod, what is your greatest safety concern?

* When escalating from a front-line therapy to natalizumab, what is your greatest safety concern?

* When escalating from a front-line therapy to ocrelizumab, what is your greatest safety concern?

* When escalating from a front-line therapy to alemtuzumab, what is your greatest safety concern?

* Of the second-line therapies, which do you think is the least problematic to switch from?

Recommend to a Colleague

Related Posts

Go back to home page